title: AFCo1 as nasal adjuvant of capsular polysaccharide from Neisseria meningitidis serogroup C induces systemic and mucosal immune responses.
abstract: Increasing emphasis is being placed on the mucosal administration of vaccines in order to stimulate mucosal as well as systemic responses. Findings from our group suggest that proteoliposome-derived cochleate (AFCo1) acts as a potent mucosal adjuvant. As an alternative to chemical conjugation, the current study aimed to determine the benefit of using AFCo1 to improve the mucosal and systemic immune responses to capsular polysaccharide of Neisseria meningitidis serogroup C (PsC), a model of a thymus-independent (TI) antigen. Therefore, intranasal (i.n.) immunization of 3 doses 1 week apart with AFCo1 plus PsC in mice was conducted. Highly specific anti-PsC IgA responses and an anti-PsC IgG response were obtained. The subclass pattern induced against PsC was similar to that induced with the meningococcal vaccine. In summary, AFCo1 as nasal adjuvant was demonstrated to be capable of eliciting mucosal and systemic specific responses against a TI antigen.
authors.affiliation: Immunology Department, Havana, Cuba. bromeu@finlay.edu.cu
authors.forename: Belkis
authors.initials: B
authors.lastname: Romeu
authors.forename: Elizabeth
authors.initials: E
authors.lastname: González
authors.forename: Caridad
authors.initials: C
authors.lastname: Zayas
authors.forename: Judith
authors.initials: J
authors.lastname: Del Campo
authors.forename: Reinaldo
authors.initials: R
authors.lastname: Acevedo
authors.forename: Maribel
authors.initials: M
authors.lastname: Cuello
authors.forename: Yolanda
authors.initials: Y
authors.lastname: Valdes
authors.forename: Julio
authors.initials: J
authors.lastname: Balboa
authors.forename: Osmir
authors.initials: O
authors.lastname: Cabrera
authors.forename: Miriam
authors.initials: M
authors.lastname: Lastre
authors.forename: Oliver
authors.initials: O
authors.lastname: Pérez
mesh_terms: D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000281:Administration, Intranasal; D000818:Animals; D000907:Antibodies, Bacterial / Q000032:analysis / Q000097:blood; D000942:Antigens, Bacterial / Q000276:immunology*; D016667:Bacterial Capsules / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D007070:Immunoglobulin A / Q000032:analysis; D007074:Immunoglobulin G / Q000097:blood; D007273:Injections, Intramuscular; D008589:Meningococcal Infections / Q000276:immunology / Q000517:prevention & control; D022401:Meningococcal Vaccines / Q000276:immunology / Q000494:pharmacology*; D051379:Mice; D008807:Mice, Inbred BALB C; D038542:Neisseria meningitidis, Serogroup C / Q000737:chemistry / Q000276:immunology*; D011510:Proteolipids / Q000276:immunology / Q000494:pharmacology*
chemical_list: D000276:Adjuvants, Immunologic; D000907:Antibodies, Bacterial; D000942:Antigens, Bacterial; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D022401:Meningococcal Vaccines; D011510:Proteolipids; C020485:proteoliposomes